<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01029522</url>
  </required_header>
  <id_info>
    <org_study_id>224CHL08F</org_study_id>
    <nct_id>NCT01029522</nct_id>
  </id_info>
  <brief_title>Dyslipidemia in Cardiovascular Disease</brief_title>
  <acronym>KoLipilou</acronym>
  <official_title>A Multi-center, Randomized, Double-blinded Equivalence Clinical Trial to Evaluate Efficacy and Safety of LipiLou 20 mg Versus Lipitor 20 mg in Hypercholesterolemic Patients With Higher Risk Cardiovascular Disease in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, double-blinded equivalence clinical trial to evaluate efficacy&#xD;
      and safety of LipiLou 20 mg versus Lipitor 20 mg in hypercholesterolemic patients with higher&#xD;
      risk cardiovascular disease in Korea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C</measure>
    <time_frame>after taken medicine for 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Lipilou 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lipitor 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin (Lipilou)</intervention_name>
    <description>treatment of dyslipidemia administration : PO, qod</description>
    <arm_group_label>Lipilou 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin (Lipitor)</intervention_name>
    <description>treatment of dyslipidemia administration : PO, qod</description>
    <arm_group_label>Lipitor 20mg</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Dyslipidemic patients with high-risk cardiovascular disease meeting more than 1&#xD;
             requirement below (LDL-C ≥ 100mg/dL) 1) Coronary artery disease&#xD;
&#xD;
               -  diagnosed with atheroma in Coronary CT or Angiography, or SPECT positive or&#xD;
                  Treadmill test positive 2) Diabetes Mellitus 3) intervened with stent in coronary&#xD;
                  artery disease more than 1 year before 4) diagnosed with atheroma in carotid&#xD;
                  artery 5) Peripheral artery disease&#xD;
&#xD;
          2. Aged 20~85 years&#xD;
&#xD;
          3. Volunteers consented with participating clinical trial and submitted consent paper&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Experimental examination at screening 1) Active liver disease or more than 2 x ULN of&#xD;
             AST/ALT 2) Creatine Kinase &gt; 2 x ULN 3) Creatinine &gt; 2.5mg/dL 4) Triglycerides &gt;&#xD;
             500mg/dL&#xD;
&#xD;
          2. intervened with stent in coronary artery disease less than 1 year before&#xD;
&#xD;
          3. Hyper-sensitive or resistant to other HMG-CoA reductase inhibitors, or experienced&#xD;
             serious adverse events&#xD;
&#xD;
          4. Patients taking dyslipidemic treatments within 4 weeks (HMG-CoA reductase inhibitors,&#xD;
             fibrates, nicotinic acids or bile acid resins, etc.)&#xD;
&#xD;
          5. As uncontrolled DM patients, HbA1c≥11% or fasting plasma glucose ≥200mg/dL&#xD;
&#xD;
          6. DBP &gt; 100mmHg, SBP &gt; 160mmHg&#xD;
&#xD;
          7. Diagnosed with myopathy&#xD;
&#xD;
          8. Appear to be a risk of myopathy below&#xD;
&#xD;
               -  renal impairment or prior renal dysfunction&#xD;
&#xD;
               -  hypothyroidism&#xD;
&#xD;
               -  genetic defects or family history of myopathy&#xD;
&#xD;
               -  experienced prior muscle toxicity with taking statins or fibrates&#xD;
&#xD;
               -  prior liver disease or higher intakes of alcohol&#xD;
&#xD;
               -  aged over 70, and a risk of myopathy&#xD;
&#xD;
          9. Women pregnant or breast-feeding&#xD;
&#xD;
         10. Women capable of pregnancy without using contraceptives&#xD;
&#xD;
         11. contra-indicated medically or mentally, or forbidden legally&#xD;
&#xD;
         12. Enrolled to other clinical trial within 4 weeks&#xD;
&#xD;
         13. Impossible to participate clinical trial according to investigator's decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KIM hyo soo, ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>yongon-dong, jong-ro gu, Seoul National University Hospital, South of Korea</affiliation>
  </overall_official>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>August 8, 2012</last_update_submitted>
  <last_update_submitted_qc>August 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

